The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)

PHASE3CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Pneumonia, Bacterial
Interventions
DRUG

ampicillin sodium/sulbactam sodium

ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days

Trial Locations (22)

Unknown

Tosei General Hospital, Seto-shi

Fukuoka Sanno Hospital, Fukuoka

National Hospital Organization Kokura Medical Center, Kitakyushu

University of Occupational and Environmental Health, Kitakyushu

Nagata Hospital, Yanagawa

National Hospital Organization Asahikawa Medical Center, Asahikawa

National Hokkaido Medical Center, Sapporo

National Hospital Organization Himeji Medical Center, Himejishi

KKR Takamatsu Hospital, Takamatsu

Nippon Koukan Hospital, Kawasaki

Kanagawa Cardiovascular and Respiratory Center, Yokohama

National Hospital Organization Kochi National Hospital, Kochi

National Hospital Organization Kumamoto Saishyunsou Hospital, Koushi-shi

Saiseikai Kumamoto Hospital, Kumamoto

Saka General Hospital/Respiratory, Shiogama

National Hospital Organization Matsumoto Medical Center Chushin Matsumoto Hospital, Matsumoto

Japanese Red Cross Nagasaki Genbaku Isahaya Hospital, Isahaya

Nagasaki University School of Medicine, Nagasaki

National Hospital Organization Minami-Okayama Medical Center, Tsukubo-gun

National Hospital Organization Ureshino Medical Center, Ureshino-shi

Sekishinkai Sayama Hospital, Sayama

National Hospital Organization Tenryu National Hospital, Hamamatsu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY